Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • District of Columbia - United States Medical cannabis bill increasing access becomes law…
  • United States - Washington Interstate cannabis trade bill passes Senate and heads to House…
  • South Dakota - United States Governor vetoes industrial hemp revision bill…
  • South Dakota - United States Medical cannabis use prohibited if pregnant or breastfeeding…
  • South Dakota - United States Governor signs bill on medical cannabis qualifying conditions…
  • Oklahoma - United States Medical cannabis-related bill passes Senate…
  • Kentucky - United States Delta-8 THC bill signed by governor and becomes law…
  • Europe EC reveals environmental claims proposal…
  • Spain Parties rally behind Podemos proposal for hemp regulation…
  • Maryland - United States Personal use cannabis good, ‘volume dealing’ bad, House says…
  • North Dakota - United States Legislature approves easier cannabis rules for over-65s in hospices…
  • New Hampshire - United States House backs home growing for medical cannabis patients…
View all
Regulatory reports

CBD classed as pharmaceutical product: Taiwan regulatory report

Written by || 24th January 2019 || Regulatory reports | Health and science | Marketing and retailing | Policy and Politics | Regulation and legislation | Asia Taiwan

In our report looking at the regulations governing CBD in Taiwan, we find that CBD is a classified as a pharmaceutical product and the growing of cannabis plants for any purposes including the extraction, and the addition of CBD to cosmetic products, is prohibited.

...
Free Sample

Table of contents

1 Executive summary 2 Planting and growing 3 Extraction and manufacture 4 Importing and exporting 5 Pure CBD isolate and flower 6 Finished products 7 Regulations 8 Relevant bodies

Need help?

Contact a sales representative right now and don’t wait

Email us

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

VIEW REPORTS

Get a free sample of this report:

“ CBD classed as pharmaceutical product: Taiwan regulatory report ”






    Buy report request information:

    “ CBD classed as pharmaceutical product: Taiwan regulatory report ”






      Sign up to our platform and you will have access to our latest business and regulatory news analysis, which keeps you updated with the latest hot topics in the sector.

      FREE TRIAL

      CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.

      © 2023 Tamarind Media Limited (T/A CannIntelligence)
      CannIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CannIntelligence, does not accept any liability or responsibility for information or views published.